Merck Serono, the biopharma business of Merck, Darmstadt, Germany, has adopted Genedata Biologics® as their central workflow platform at biopharma R&D units in Germany, Israel, and the US, where the company is called EMD Serono. Using Genedata Biologics, Merck Serono is streamlining its large-molecule research processes to increase both productivity and quality. The platform addresses Merck Serono’s proprietary workflows and technologies, such as their high-throughput B-cell screening platform, as well as protein engineering workflows for next-generation antibody formats, and novel library technologies. The system is being deployed across different biopharma research centers and is harmonizing all biologics discovery processes, including molecular biology, expression, purification, and analytics processes. It is fully integrated into Merck Serono’s IT landscape and laboratory infrastructure.